Avastin To Be Standard Add-On Agent In Colorectal Cancer, Genentech Says
Executive Summary
Genentech believes that its investigational agent Avastin will become standard add-on therapy to chemotherapy in the treatment of colorectal cancer after unveiling data demonstrating that the VEGF inhibitor "markedly" improves survival in first-line metastatic disease
You may also be interested in...
Genentech Avastin Clears FDA; Colorectal Cancer Drug Costs $4,400 A Month
Genentech is launching its oncologic Avastin at a wholesale acquisition cost of $2,200 per dose for the average colorectal cancer patient
Genentech Avastin Clears FDA; Colorectal Cancer Drug Costs $4,400 A Month
Genentech is launching its oncologic Avastin at a wholesale acquisition cost of $2,200 per dose for the average colorectal cancer patient
Gilead Leads Biotech Rebound In 2003: Product Stories Play Well
Gilead Sciences is leading a new wave of biotech stocks attempting to break out of the start-up phase to become full-fledged biopharma companies